as 06-20-2025 4:00pm EST
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Founded: | 1999 | Country: | United States |
Employees: | N/A | City: | LOS ANGELES |
Market Cap: | 861.0M | IPO Year: | N/A |
Target Price: | $16.67 | AVG Volume (30 days): | 908.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.18 | EPS Growth: | N/A |
52 Week Low/High: | $2.31 - $14.49 | Next Earning Date: | 08-06-2025 |
Revenue: | $107,925,000 | Revenue Growth: | 29.77% |
Revenue Growth (this year): | 26.21% | Revenue Growth (next year): | 20.91% |
NAGE Breaking Stock News: Dive into NAGE Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Business Wire
10 days ago
Business Wire
12 days ago
Business Wire
17 days ago
Simply Wall St.
19 days ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
The information presented on this page, "NAGE Niagen Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.